Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Shares Sold by Forsta AP Fonden

Forsta AP Fonden lessened its stake in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 9.8% in the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 22,100 shares of the biopharmaceutical company's stock after selling 2,400 shares during the period. Forsta AP Fonden's holdings in Regeneron Pharmaceuticals were worth $15,742,000 at the end of the most recent reporting period.

A number of other large investors have also added to or reduced their stakes in REGN. Rakuten Securities Inc. lifted its holdings in shares of Regeneron Pharmaceuticals by 380.0% during the third quarter. Rakuten Securities Inc. now owns 24 shares of the biopharmaceutical company's stock valued at $25,000 after purchasing an additional 19 shares in the last quarter. FSA Wealth Management LLC purchased a new stake in Regeneron Pharmaceuticals in the third quarter worth approximately $26,000. Fairfield Financial Advisors LTD bought a new stake in Regeneron Pharmaceuticals in the 3rd quarter worth approximately $37,000. Truvestments Capital LLC bought a new position in shares of Regeneron Pharmaceuticals during the 3rd quarter valued at $39,000. Finally, Valley Wealth Managers Inc. purchased a new position in shares of Regeneron Pharmaceuticals in the 3rd quarter worth $49,000. Hedge funds and other institutional investors own 83.31% of the company's stock.

Regeneron Pharmaceuticals Stock Performance

Shares of NASDAQ REGN traded down $9.29 during midday trading on Thursday, reaching $677.98. The company had a trading volume of 181,968 shares, compared to its average volume of 851,999. The stock has a market cap of $74.50 billion, a P/E ratio of 16.76, a P/E/G ratio of 1.59 and a beta of 0.10. The company has a current ratio of 5.28, a quick ratio of 4.46 and a debt-to-equity ratio of 0.09. The business's 50-day simple moving average is $723.36 and its 200 day simple moving average is $928.61. Regeneron Pharmaceuticals, Inc. has a 1 year low of $666.25 and a 1 year high of $1,211.20.

Analyst Ratings Changes

REGN has been the topic of several research reports. StockNews.com cut Regeneron Pharmaceuticals from a "strong-buy" rating to a "buy" rating in a research report on Monday, November 4th. Piper Sandler dropped their price target on shares of Regeneron Pharmaceuticals from $1,195.00 to $1,013.00 and set an "overweight" rating for the company in a research report on Monday. JPMorgan Chase & Co. reduced their price objective on shares of Regeneron Pharmaceuticals from $1,200.00 to $1,150.00 and set an "overweight" rating for the company in a research note on Thursday, October 24th. UBS Group cut shares of Regeneron Pharmaceuticals from a "buy" rating to a "neutral" rating and lowered their target price for the company from $1,130.00 to $738.00 in a research note on Thursday, January 16th. Finally, Wells Fargo & Company decreased their price target on Regeneron Pharmaceuticals from $1,050.00 to $900.00 and set an "overweight" rating on the stock in a report on Friday, January 10th. One analyst has rated the stock with a sell rating, seven have given a hold rating, fifteen have issued a buy rating and one has assigned a strong buy rating to the company's stock. Based on data from MarketBeat, Regeneron Pharmaceuticals presently has an average rating of "Moderate Buy" and an average price target of $1,004.57.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.